Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could ease pain after hip surgery without opioids

NCT ID NCT07543796

Symptom relief Sponsor: Beijing Tide Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new painkiller called TRD205 for people recovering from hip replacement surgery. About 200 adults will receive either TRD205, a placebo, or an active comparator (celecoxib) to see how well it controls pain and reduces the need for rescue opioids. The goal is to find a safer, effective option for postoperative pain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TRD205 tablets
What this could lead to
If successful, this could provide a new, non-opioid option for managing pain after hip replacement surgery, potentially reducing reliance on opioids.
What could go wrong
This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. The drug may not prove more effective than existing painkillers or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide written informed consent * Age 18 to 80 years, inclusive * BMI 18-32 kg/m² * ASA physical status I-II * Scheduled for elective unilateral total hip arthroplasty under general anesthesia * Able to understand study procedures and pain rating scales Exclusion Criteria: * Hypersensitivity to TRD205, celecoxib, or study-related medications * Use of prohibited analgesics, sedatives, CYP3A4 inhibitors/inducers, or analgesic herbs within specified washout periods * Inability to take oral medications postoperatively * Ipsilateral hip surgery within 1 year; contralateral hip surgery within 1 month * Hip revision surgery, developmental dysplasia Crowe type IV, or tumor involving hip * Clinically significant hemodynamic instability or cardiac arrhythmia * Severe hepatic, renal, cardiovascular, or metabolic disease * History of NSAID-induced asthma, active peptic ulcer disease * Drug or alcohol abuse within 1 year * Pregnancy, breastfeeding, or lack of effective contraception * Participation in another interventional clinical trial within 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative analgesia after unilateral hip arthroplasty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postoperative analgesia after unilateral hip arthroplasty

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Third Affiliated Hospital of Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 130021, China